The International Journal of Biochemistry & Cell Biology, published by Pergamon-Elsevier Science Ltd, stands as a pivotal resource in the fields of biochemistry and cell biology. With an ISSN of 1357-2725 and an E-ISSN of 1878-5875, this prestigious journal has been a key platform for disseminating cutting-edge research since its inception in 1995. The journal currently holds an impressive Q1 ranking in Biochemistry and a Q2 ranking in Cell Biology for the year 2023, reflecting its commitment to high-quality research and its influence within the scientific community. With a significant Scopus ranking of 94/438 in Biochemistry and 96/285 in Cell Biology, the journal plays a crucial role in advancing knowledge and fostering innovative approaches in these dynamic fields. Though it is not an open-access journal, the International Journal of Biochemistry & Cell Biology remains accessible to a wide audience, making it a vital resource for researchers, professionals, and students alike, who are eager to explore and contribute to the ongoing advancements in biochemistry and cell biology.

STRESS - THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS, published by Taylor & Francis Ltd, is an esteemed open-access journal dedicated to advancing our understanding of stress and its biological underpinnings. Established in 1996 and continuing until 2024, this journal is pivotal in the exploration of stress across multiple dimensions, including its impact on mental health, neurobiology, and endocrine systems. With an impressive categorization in Q2 and Q3 quartiles across various fields such as Behavioral Neuroscience, Psychiatry, and Physiology, STRESS ranks commendably within its discipline, positioning itself as a vital resource for researchers and professionals alike. As of 2022, the journal's open access policy enhances visibility and accessibility, fostering a broader dissemination of knowledge. The journal invites submissions from a diverse range of disciplines, aiming to bridge gaps across fields and encourage interdisciplinary collaboration. By addressing the multifaceted nature of stress, STRESS remains essential for those eager to contribute to this dynamic and critical area of research.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, published by Academic Press Inc Elsevier Science, stands as a leading periodical in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an ISSN of 0006-291X and an E-ISSN of 1090-2104, this esteemed journal has been a pivotal platform for the dissemination of groundbreaking research since its inception in 1959, continuing to publish influential findings through at least 2024. It holds a commendable Q2 ranking in Biochemistry and Q1 status in Biophysics as of 2023, reflecting its high impact and relevance in the field, supported by its strong Scopus rankings—ranking #43 in Biophysics and maintaining a presence in the top quartiles of several related categories. Although it is not an open-access journal, it provides critical insights and essential data that cater to researchers, professionals, and students keen on advancing their understanding of complex biochemical and biophysical processes. Its significant contributions to the scientific community underscore the importance of this journal as a reference point for innovative research and collaborative discourse.

JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY is a distinguished publication presented by the POLISH PHYSIOLOGICAL SOC, dedicated to advancing the fields of physiology and pharmacology. Since its inception in 1991, this journal has maintained a commitment to disseminating vital research findings, contributing to the growing body of knowledge essential for understanding complex biological systems and their interactions with pharmacological agents. With a consistent focus on interdisciplinary studies, the journal holds a Q3 categorization in both Medicine and Pharmacology as well as Physiology for 2023, reflecting its relevance in these crucial fields. Although specific access options are not available, the journal's robust indexing and rankings in Scopus signify its credibility and the high caliber of its contributions, appealing to researchers, professionals, and students alike. Operating from the picturesque Jagiellonian University in Krakow, Poland, this journal not only enriches the academic landscape but also fosters global collaboration and innovation in the life sciences.

Frontiers in Molecular Biosciences is an esteemed open-access journal published by FRONTIERS MEDIA SA, based in Switzerland. Since its inception in 2014, the journal has made significant strides in the fields of biochemistry, genetics, and molecular biology, cementing its reputation with a solid position in the Q1 quartile for both Biochemistry and Genetics and Molecular Biology (miscellaneous) categories as of 2023. With a remarkable Scopus rank of #14/103 in the combined categories, it offers an essential platform for the dissemination of high-quality research that shapes the understanding of molecular processes and their implications in health and disease. The journal’s commitment to open access facilitates the broadest possible reach for groundbreaking discoveries, serving as a vital resource for researchers, professionals, and students alike. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, this journal continues to foster innovative discussions and advancements in molecular biosciences, paving the way for new insights and collaborations in the scientific community.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, published by Elsevier Science Ltd, is a premier scholarly journal dedicated to advancing the field of cardiology and cardiovascular medicine as well as molecular biology. With an impressive Q1 ranking in both categories as of 2023, the journal boasts a significant influence in the scientific community, evidenced by its Scopus rankings—33rd out of 387 in Cardiology and 65th out of 410 in Molecular Biology. Established in 1970 and continuing to publish groundbreaking research through 2024, the journal’s mission is to disseminate innovative findings that enhance our understanding of cardiovascular health at the molecular and cellular levels. Although it is not an open-access publication, it attracts top-tier research contributions, making it essential reading for researchers, healthcare professionals, and students aiming to stay ahead in the dynamic domains of cardiovascular and molecular biology research.

Archives of Physiology and Biochemistry, published by Taylor & Francis Ltd, is a renowned journal that has been pivotal in advancing knowledge and research in the fields of physiology and biochemistry since its inception. With an impact factor reflective of its significant contributions, this journal is categorized in Q2 in Medicine (miscellaneous) and Q3 in Physiology, underscoring its relevance and scholarly impact within the scientific community. The journal publishes original research articles, review papers, and innovative methodologies that explore the intricate relationships between physiological functions and biochemical processes. With its commitment to fostering scientific discourse, the Archives of Physiology and Biochemistry serves as an essential resource for researchers, professionals, and students alike, providing insights and evidence that drive forward the frontiers of medical and physiological science. The journal is accessible in both print and online formats, ensuring that critical research reaches a wide audience.

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.